Fly News Breaks for February 27, 2020
Feb 27, 2020 | 07:14 EDT
Barclays analyst Carter Gould initiated coverage of Eli Lilly with an Overweight rating and $160 price target. Gould has conviction in the growth outlook and durability of its diabetes business, sees improving optionality around its oncology franchise, and believes operating margins can continue to improve through 2026. The analyst initiated coverage of the U.S. Biopharmaceuticals industry with a Positive view citing waning near-term concerns on drug pricing reform, evidence of innovation and attractive valuations.
News For LLY From the Last 2 Days
There are no results for your query LLY